SCHEMBL6286002

SCHEMBL6286002

COc1ccc(-c2cc3nccnc3[nH]2)cc1NC(=S)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 4/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 1/20 0.49
CCNB2 O95067 8/20 0.47
CDK1 P06493 8/20 0.47
CCNB1 P14635 8/20 0.47
CCNB3 Q8WWL7 8/20 0.47
GSK3A P49840 7/20 0.47
GSK3B P49841 7/20 0.47
CDK5 Q00535 5/20 0.47
CDK5R1 Q15078 5/20 0.47
GAA P10253 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288171 0.87 KMT2A (0.49) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6279218 0.86 RIPK1 (0.55) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6285013 0.85 ALDH1A1 (0.47) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6288130 0.83 KMT2A (0.47) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6288146 0.82 ALDH1A1 (0.48) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6288128 0.82 KMT2A (0.52) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6288185 0.82 KMT2A (0.47) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6285927 0.82 KMT2A (0.52) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6286947 0.82 KMT2A (0.52) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL6286246 0.81 KMT2A (0.49) KMT2AALDH1A1MEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B KMT2A 4200/4885ALDH1A1 522/4885MEN1 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.